<DOC>
	<DOCNO>NCT02395172</DOCNO>
	<brief_summary>To demonstrate superiority regard overall survival avelumab versus docetaxel subject program death ligand 1 ( PD-L1 ) positive , non-small cell lung cancer ( NSCLC ) failure platinum-based doublet .</brief_summary>
	<brief_title>Avelumab Non-Small Cell Lung Cancer ( JAVELIN Lung 200 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Inclusion Criteria Signed write informed consent trial related procedure Male female subject age great equal ( &gt; = ) 18 year Availability formalinfixed , paraffinembedded block contain tumor tissue 7 unstained tumor slide suitable PDL1 expression assessment Tumor determine evaluable PDL1 expression per evaluation central laboratory Subjects histologically confirm Stage IIIb/IV recurrent NSCLC experience disease progression Subjects must progress acceptable therapy define follow : 1 . Subjects must progress minimum 2 cycle 1 course platinum base combination therapy administer treatment metastatic disease . A history continuation ( use non platinum agent initial combination ) switch ( use different agent ) maintenance therapy permit provided progression initial combination . A switch agent treatment management toxicity also permit provided progression initial combination OR 2 . Subjects must progress within 6 month completion platinumbased adjuvant , neoadjuvant , definitive chemotherapy , concomitant chemoradiation regimen locally advance disease Subjects nonsquamous cell NSCLC unknown epidermal growth factor receptor ( EGFR ) mutation status require testing ( local laboratory , central laboratory local test available ) . Subjects tumor harbor activate EGFR mutation eligible Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 1 trial entry Estimated life expectancy 12 week Adequate hematological function define White Blood Cell ( WBC ) count &gt; = 2.5 × 10^9/L absolute neutrophil count ( ANC ) &gt; = 1.5 × 10^9/L , lymphocyte count &gt; =0.5 × 10^9/L , platelet count &gt; = 100 × 10^9/L , hemoglobin &gt; = 9 gram per deciliter ( g/dL ) ( may transfuse ) Adequate hepatic function define total bilirubin level less equal ( &lt; = ) 1.5 × upper limit normal ( ULN ) range aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) level &lt; = 2.5 × ULN subject Adequate renal function define estimate creatinine clearance &gt; 30 milliliter per minute ( mL/min ) accord CockcroftGault formula ( local institutional standard method ) . Other protocol define inclusion criterion could apply Exclusion criterion In United States , subject squamous cell histology exclude Systemic anticancer therapy administer disease progression follow platinum base combination Subjects nonsquamous cell NSCLC whose disease harbor EGFR mutation ( ) and/or anaplastic lymphoma kinase ( ALK ) rearrangement eligible trial . Subjects unknown ALK and/or EGFR mutation status require test screening ( local laboratory , central laboratory local test available ) Prior therapy antibody/drug target T cell coregulatory protein ( immune checkpoint ) PD1 , PD L1 , cytotoxic T lymphocyte antigen4 ( CTLA4 ) . Concurrent anticancer treatment Major surgery reason , except diagnostic biopsy , within 4 week randomization and/or subject fully recover surgery within 4 week randomization Subjects receive immunosuppressive agent ( steroid ) reason taper drug initiation trial treatment . All subject brain metastasis , except meet follow criterion : 1 . Brain metastasis treat locally , 2 . No ongoing neurological symptom relate brain localization disease Active autoimmune disease might deteriorate receive immunostimulatory agent : 1 . Subjects diabetes type I , vitiligo , psoriasis , hypo hyperthyroid disease require immunosuppressive treatment eligible 2 . Subjects require hormone replacement corticosteroid eligible steroid administer purpose hormonal replacement dose less equal ( &lt; = ) 10 milligram ( mg ) equivalent prednisone per day 3 . Administration steroids route know result minimal systemic exposure acceptable Previous ongoing administration systemic steroid management acute allergic phenomenon acceptable long anticipated administration steroid complete 14 day , daily dose 14 day &lt; =10 mg per day equivalent prednisone Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>avelumab</keyword>
	<keyword>MSB0010718C</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Anti-PD-L1</keyword>
</DOC>